share_log

Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $12 Price Target

Benzinga ·  Sep 29, 2023 10:22

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment